The Priority Review

Tag

Jiangsu HengRui Medicine Co., Ltd.

1 story

  1. Clinical trials

    Jiangsu HengRui registers Phase III trial of HRS-6209 plus letrozole in advanced breast cancer

    The study, led by Jiangsu HengRui Medicine Co., Ltd., plans to enroll 1050 participants and begin on November 20, 2026. It compares HRS-6209 plus letrozole with dalpciclib or palbociclib plus aromatase inhibitor in patients with advanced or metastatic breast cancer who have not received prior systemic treatment.